Are you a health care worker? We’d love to hear from you. Email editor at northcarolinahealthnews.org

By Rose Hoban

The science of tracking the novel coronavirus’ spread took on a political tinge Wednesday with Senate leader Phil Berger (R-Eden) participating in the rollout of a research study to track people who may have already had COVID-19 without knowing it.

Berger announced earlier this week that $100,000 in discretionary funding from the North Carolina General Assembly is going to help start a study tracking symptoms and blood samples from patients at Charlotte’s Atrium Health and Winston-Salem’s Wake Forest Baptist Health who volunteer to be part of the research.

In a telephone press conference Wednesday morning, senate leader Phil Berger (R-Eden) touted the new study as “a worthy investment, just to get the data to help inform decisions.”

He also took a swipe at health and human services Secretary Mandy Cohen telling reporters that she had been “resistant to prioritizing sample testing.”

“We made the decision that because of ongoing resistance that we would continue to look for partnerships that could provide us with that type of testing, and that type of data,” Berger said.

Later in the day, Cohen pushed back during an afternoon press conference saying that she was unaware of the Wake Forest Baptist study until she learned of it Tuesday. It was then that scientists affiliated with DHHS reached out.

Cohen has been adamant that the state use it’s limited capacity for testing current COVID patients strategically, prioritizing those arriving at health care facilities with symptoms.

“Personal protective equipment, the gowns, the masks, the gloves continue to be a limiting factor,” Cohen said. “Those shortages of protective equipment, those gowns and masks, mean we must be judicious in how we use these resources and that also means that has to be available for our health care workers who care for those with COVID-19.”

But the back and forth portends a larger political battle that’s looming over lifting the strict social distancing measures that have kept North Carolinians hunkered down in their homes for more than a month.

Tests look back

Wake Forest Baptist Health physician and researcher John Sanders is leading the study that’s got Berger’s backing. Sanders told reporters during the morning call that the study will focus on identifying those who may have had COVID in the past and who now have antibodies against the disease.

Antibody testing is one part of determining the population’s exposure to COVID. People who have been exposed make antibodies to the virus, but there’s still some question whether those antibodies confer long-term immunity to the disease. Nonetheless, they’re a significant marker to help scientists know how many people have been exposed to a disease that some estimate may not cause any symptoms at all in some people.

Graph from a document released by Gov. Roy Cooper’s office in his plan to ease social distancing restrictions and support North Carolina’s economic recovery. North Carolina’s current death rate is 12/ million people, putting the state 42nd in the country in deaths, lower than all of our neighboring states. By comparison, New York has had 597 deaths/ million people and Virginia has had 23 deaths/ million people.

The COVID-19 Community Research Partnership will send at least a thousand patients home test kits, which are similar to a home pregnancy test.

“A plastic kit to put a sample on, in this case, a drop of blood,” Sanders said. “In a few minutes you get a few lines that tell you whether you’ve got antibodies, or not.”

The sample of people will not be representative of the greater population, something Sanders acknowledged is a weakness of the study because the sample population will not be completely random.

The federal Food and Drug Administration has yet to approve these home test kits, made by a company called Scanwell, which only has approval for use in a research setting, or any other test kits. Just this week, the agency said it was working with developers of such tests to allow for emergency authorization of the tests. The agency also raised concerns “including whether the lay user can safely and properly collect the specimen, whether the components of the specimen transport media are safe for use in the home environment (since some may be toxic), proper shipment, and adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions (such as, if the specimen sits in a hot truck).”

So, part of the study will be helping Scanwell validate it’s testing apparatus.

That will be done by sending another test, where subjects will prick their fingers to draw a microsample of blood that will be sent to researchers for an in-lab antibody analysis.

National Institutes of Health researcher Kaitlyn Sadtler, holds up a blood microsampling device made by Neoteryx, the same technology that will be used the Wake Forest Baptist study for in-home blood collection. Photo courtesy: NIH/ NBIB

Finally, all of the data will be gathered on a database created by the database company Oracle, which will also create a portal for patients to enter their own symptoms, such as fever, cough, shortness of breath, and contacts with patients who turn up positive for the virus.

The samples will be linked to patients’ electronic medical records and will be put up against the blood sampling kit to compare to the results patients get from the home test with what researchers are seeing in the community.

Sanders called the General Assembly money a “kickstarter.” He’s also in talks with the National Institutes of Health and the Centers for Disease Control and Prevention for further funding, which he estimated could be in the tens of millions of dollars when the study gets up to scale.

Back and forth

The Wake Forest-led study comes at a time when there’s an increased call for relaxation of the strict social distancing rules that Gov. Roy Cooper and governors around the country have enacted to retard the spread of COVID-19. In recent weeks, Berger’s office has released several documents calling for more testing to drive decision-making around the economy.

“Without clearer data-driven evidence to support the continued economic shutdown, fewer and fewer people will comply with government orders over time. If the situation is as bad or worse than projected, then this data will instill confidence in government decisions and increase compliance, which would be necessary for an effective public health strategy,” said an April 13 release published on Medium.

“If the data shows the situation is better than projected, then we can have confidence that unwinding the economic shutdown can be done safely,” the release says.

But Cooper and Cohen pushed back against Berger later in the day. When asked about the Berger-backed study during the daily briefing on COVID, Cohen said there’s a lot of research ongoing with scientists who are collaborating with the Department of Health and Human Services.

“I want to make sure that we’re using our underlying infrastructure that our state has invested in over a number of years to do surveillance for disease and how we can leverage that going forward,” she said. “Coordination and data sharing is always going to be important here because there are going to be different kinds of research that are needed to understand different facets of the virus.”

She said that she also wanted antibody testing for COVID, along with a reliable test for seeing who has the disease now.

“I think all of these pieces are important in order to paint a picture. I think we are going to have this picture evolve over many weeks and months that will help us tailor our decisions,” she said. “We’re working with partners at UNC and Duke with a different type of methodology.

“It’s important that we need to come together in a coordinated look at the virus across our state.”

Later in the day, Cooper’s office released a document outlining his three-pronged plan for making the fraught decisions around undoing social distancing restrictions. The worry is that lifting restrictions will result in a spike of illnesses that overwhelm hospitals, leading to more deaths.

Clarification: This story has been changed to reflect that the fact this study uses a “convenience sample” of patients and is not representative of  the population is a weakness of the study design.

Rose Hoban

Rose Hoban is the founder and editor of NC Health News, as well as being the state government reporter. Hoban has been a registered nurse since 1992, but transitioned to journalism after earning degrees...

2 replies on “General Assembly leaders supported a study on COVID with $100,000. What will it tell us going forward?”

  1. Apparently none of this was run by the state DHHS, per Cooper’s covid update yesterday they had just been made aware of this study. This type of effort should not be done on the sly – whoever proceeded with these research efforts and used taxpayer $$ to do it needs to be investigated. This is no time for local hospitals or governments to go rogue. So very disappointing that this was done in a vacuum.

  2. All studies like this must be reported to the Federal Government. This one is listed here:
    https://clinicaltrials.gov/ct2/show/NCT04342884 (Note: we usually eliminate links, but this provides important context)

    The at-home test will be developed by Scanwell, a Los Angeles startup funded by the Founders Fund, a Peter Thiel venture fund which may help them get support from Trump given Thiel’s support for Thump ($1M campaign contribution, etc.). But the test they are developing is being made in China: “The test kits are manufactured by Innovita, a Beijing biotech company, that has an exclusive three-year U.S. partnership with Scanwell. Innovita, which Jeng says has the capacity to produce 500,000 kits a day, has distributed tests in China, Iran, and the Czech Republic.” Even if the at-home test is eventually shown to be accurate, the current trade war and export controls China just implemented in response to Trump will probably impact direct export to the US.

    Finally, Scanwell’s own Chief Medical Officer explains that this at-home test has limitations. From the NBC news story, which is actually listed on the Scanwell press website: “Jeng himself has a conservative take about an immediate return to the workforce. He said antibody tests are only one piece of the diagnostic puzzle. “Thinking that you’re completely immune,” he said, “may put you at risk.””

    So, Berger has chosen to spend his $100K discretionary money on a study of 1000 patients from Western North Carolina that will use an at-home test manufactured in China and not yet approved for use in the US and the results will be be available for 12 months or, as they report, December 21. Beyond that, Berger decided to throw the money to Scanwell, a Los Angeles company, and not LabCorp, a NC-based company that leads the world in laboratory testing.

    Research is important, but WFBH and Scanwell didn’t need the $100K. Scanwell is flush with cash; let them, like other manufacturers, fund their own validation study. Let WFBH partner with Oracle, which also doesn’t need the money, to implement their study.

    (this comment has been edited to fit our policy of only allowing a maximum of 350 words per comment)

Comments are closed.